PK, Safety,and Efficacy of Omacetaxine in Patients With Chronic Myeloid Leukemia
- Study Title
- A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
- Teva Identifier
- C41443/2057 | 2013-005320-42
- ClinicalTrials.gov Identifier
- NCT02078960
- Study Status
- Terminated
- Trial Condition(s)
- Chronic Myeloid Leukemia
- Interventions
- Drug: Omacetaxine mepesuccinate
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- October 9, 2014 - November 27, 2017
- Phase
- Phase 1/2
